$HSCS

3 stories mentioning HSCSUpdated 46d ago

Every FINWIRES story that references HSCS, newest first.

Top Midday Gainers

Boundless Bio (BOLD) signed a definitive agreement with privately held biotech firm Serapha Bio in an all-stock merger, according to a statement Tuesday.Shares of Boundless surged 88% as intraday trading volume catapulted to over 57.5 million from a daily average of about 223,000.HeartSciences (HSCS) has agreed to merge with digital mining company Fortitude Mining in an all-stock deal, it said Tuesday.Shares jumped 52% amid a jump in intraday trading volume to over 126.9 million from a daily average of roughly 32,000.IBM (IBM) joined the OpenAI Daybreak Cyber Partner Program and launched a new application-security service that uses OpenAI's models to help enterprises identify and validate software vulnerabilities, it said late Monday.Shares rose 5.5% following an increase in intraday trading volume to over 9.3 million from a daily average of about 8.2 million.Price: $2.63, Change: $+1.23, Percent Change: +87.86%

$BOLD$HSCS$IBM

Wire46d ago

HeartSciences to Merge With Digital Asset Mining Platform Fortitude; Shares Rise Pre-Bell

HeartSciences (HSCS) said Tuesday it has agreed to merge with digital mining company Fortitude Mining in an all-stock deal.Under the agreement, Fortitude's sole shareholder, Digital Currency Group, will own approximately 95% of the combined company on a fully diluted basis at closing.The combined company is expected to trade on the Nasdaq Capital Market under the ticker symbol "TUDE."Upon closing, the combined company will operate under the Fortitude brand and be led by Fortitude's current management team. HeartSciences Chief Executive Officer Andrew Simpson will oversee the healthcare business.The merger is expected to close in H2.HeartSciences shares were up more than 70% in Tuesday pre-bell activity.Price: $3.06, Change: $+1.23, Percent Change: +70.08%

$HSCS

Wire58d ago

HeartSciences Granted European Patent for Electrocardiography Technology; Shares Fall

HeartSciences (HSCS) has secured a patent from the European Patent Office for its "Electrocardiogram-Based Assessment of Diastolic Function" technology, the healthcare information technology company said Thursday.The patent, effective April 29, covers machine-learning models and methods that estimate echocardiogram parameters for diastolic function using patient data and provides coverage in 19 European countries, the company said.Shares of HeartSciences were down 2.4% in early Thursday trading.Price: $1.84, Change: $-0.04, Percent Change: -2.39%

$HSCS

Track with the FINWIRES app suite

FolioX

Track HSCS in your portfolio

WheelAI

Analyze HSCS options with the wheel strategy

StockInsider

See market sentiment on HSCS